Omeros (NASDAQ:OMER) CAO David Borges Sells 10,000 Shares of Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the chief accounting officer owned 5,906 shares in the company, valued at approximately $111,918.70. This trade represents a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Price Performance

Omeros stock opened at $19.28 on Wednesday. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of 15.06 and a beta of 2.54. The firm has a fifty day moving average price of $12.12 and a two-hundred day moving average price of $11.87. Omeros Corporation has a fifty-two week low of $3.94 and a fifty-two week high of $19.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, sell-side analysts expect that Omeros Corporation will post -0.37 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Omeros in the 2nd quarter worth approximately $57,484,000. Vanguard Group Inc. raised its stake in shares of Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after buying an additional 666,357 shares during the period. UBS Group AG lifted its position in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC boosted its position in Omeros by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after purchasing an additional 95,979 shares during the period. Finally, State Street Corp boosted its holdings in Omeros by 26.9% in the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after buying an additional 333,798 shares during the period. Institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on OMER shares. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.